Industry Briefs: May 28, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: May 28, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Bend Research has expanded its existing hot-melt extrusion capacity with the addition of an 18-mm Leistritz twin-screw mixer/extruder. Read More

Bristol-Myers Squibb formed the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology. Read More

FEI has launched its Living Lab for structural biology research on the campus of the National Institutes of Health. Read More

Mylan and Sunovion have entered into settlement agreements in the companies’ litigation relating to generic Brovana (arformoterol tartrate) and Xopenex (levalbuterol hydrochloride).

Recipharm secures financing for a EUR 90-million ($112 million) loan facility for further acquisition of niche CDMOs, investment in existing facilities, and building long-term partnerships with major pharmaceuticals companies. Read More

People News

Amgen has announced that Kevin W. Sharer has retired from his post as CEO and the company’s board of directors has appointed Robert A. Bradway his replacement. Read More

DSM has appointed Laura Parks as president and business unit director of finished-dosage business. Read More

Onyx Scientific has appointed Brian Jolly as its European business development director. Read More

Pfizer has named Olivier Brandicourt as president and general manager of its emerging markets and established products business units. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here